MedTrace Logo

Evaluation of the Integration of Ag-RDTs for COVID-19 in MNCH, HIV and TB Services in Cameroon and Kenya

NCT05498727 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 527184

Last updated 2024-01-11

No results posted yet for this study

Summary

In many national Coronavirus Disease 2019 (COVID-19) response plans, including in Kenya and Cameroon, antigen detection tests are being used to improve access for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) testing. Targeting the populations most at risk for COVID-19 disease, including pregnant women, people living with HIV, and patients with tuberculosis (TB), and those who are the most vulnerable to transmission to other populations, can reduce the negative impact of the SARS-CoV-2 pandemic. Catalyzing COVID-19 Action (CCA) aims to strengthen detection by screening and diagnosing cases of SARS-CoV-2 in MNCH clinics, HIV clinics, and TB clinics and enhancing the management of COVID-positive cases. The main goal of the CCA project is to reduce deaths and severe illnesses caused by COVID-19 through early access to reliable diagnosis and effective treatment through innovative models of care. Both countries will conduct a pre- and post-implementation evaluation to compare screening, testing, care, and treatment of patients undergoing COVID-19 screening, testing, and treatment before and after the integration of facilities taking part in the CCA project.

Conditions

Interventions

DIAGNOSTIC_TEST

Integration of SARS-CoV 2 Testing in HIV, MNCH and TB Clinics

This study employs a quasi-experimental pre-and-post SARS-CoV-2 Ag-RDT integration design in all facilities implementing the 61 facilities in Cameroon and Kenya in Cameroon and Kenya.

Sponsors & Collaborators

  • UNITAID

    collaborator OTHER

  • Kenya Ministry of Health

    collaborator OTHER_GOV

  • Ministry of Public Health, Cameroon

    collaborator UNKNOWN

  • Elizabeth Glaser Pediatric AIDS Foundation

    lead OTHER

Principal Investigators

  • Nilesh Bhatt, MD, PhD · Elizabeth Glaser Pediatric AIDS Foundation

  • Rose Otieno Masaba, MD, MSc · Elizabeth Glaser Pediatric AIDS Foundation

  • Boris Tchounga, MD, PhD · Elizabeth Glaser Pediatric AIDS Foundation

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-02
Primary Completion
2022-10-31
Completion
2023-09-30

Countries

  • Cameroon
  • Kenya

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05498727 on ClinicalTrials.gov